| [1] |
Leung JH, Leung HWC, Wang SY, et al. Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: a Bayesian network Meta-analysis[J]. Medicine (Baltimore), 2024, 103(21): e38183. DOI: 10.1097/MD.0000000000038183.
|
| [2] |
Hamanishi J, Takeshima N, Katsumata N, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)[J]. J Clin Oncol, 2021, 39(33): 3671-3681. DOI: 10.1200/JCO.21.00334.
|
| [3] |
Bamias A, Gibbs E, Khoon Lee C, et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial[J]. Ann Oncol, 2017, 28(8): 1842-1848. DOI: 10.1093/annonc/mdx228.
|
| [4] |
|
| [5] |
Wang Z, Chen W, Zuo L, et al. The fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells[J]. Cancer Commun (Lond), 2022, 42(3): 245-265. DOI: 10.1002/cac2.12274.
|
| [6] |
|
| [7] |
Xu H, Li W, Yue H, et al. S100B induces angiogenesis via the clathrin/FOXO1/β-catenin signaling pathway and contributes to bevacizumab resistance in epithelial ovarian cancer[J]. J Adv Res, 2026, 81: 613-636. DOI: 10.1016/j.jare.2025.05.060.
|
| [8] |
Gaitskell K, Rogozińska E, Platt S, et al. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer[J]. Cochrane Database Syst Rev, 2023, 4(4): CD007930. DOI: 10.1002/14651858.CD007930.pub3.
|
| [9] |
Avril S, Dincer Y, Malinowsky K, et al. Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients[J]. Oncotarget, 2017, 8(58): 97851-97861. DOI: 10.18632/oncotarget.18415.
|
| [10] |
da S Mororó J, Meira DD, Bizzo SMD, et al. Detecting vascular normalization in epithelial ovarian cancer[J]. Med Oncol, 2025, 42(9): 401. DOI: 10.1007/s12032-025-02929-5.
|
| [11] |
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13): 1302-1308. DOI: 10.1200/JCO.2013.51.4489.
|
| [12] |
Shoji T, Enomoto T, Abe M, et al. Efficacy and safety of standard of care with/without bevacizumab for platinum- resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023[J]. Cancer Sci, 2022, 113(1): 240-250. DOI: 10.1111/cas.15185.
|
| [13] |
De Tommasi O, Pan H, Spagnol G, et al. New frontiers in the management of recurrent epithelial ovarian cancer: a comprehensive review[J]. Gynecol Obstet Clin Med, 2025, 5(4): 232-240. DOI: 10.1136/gocm-2025-000277.
|
| [14] |
Moffat GT, Kong W, MacKay HJ, et al. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer[J]. Gynecol Oncol, 2024, 184(1): 51-56. DOI: 10.1016/j.ygyno.2024.01.027.
|
| [15] |
Holloway RW, Thaker P, Mendivil AA, et al. A phase Ⅲ，multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer[J]. Int J Gynecol Cancer, 2023, 33(9): 1458-1463. DOI: 10.1136/ijgc-2023-004812.
|
| [16] |
Holloway RW, Mendivil AA, Kendrick JE, et al. Clinical activity of olvimulogene nanivacirepvec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: the nonrandomized phase 2 VIRO-15 clinical trial[J]. JAMA Oncol, 2023, 9(7): 903-908. DOI: 10.1001/jamaoncol.2023.1007.
|
| [17] |
Colombo N, Mangili G, Mammoliti S, et al. A phase Ⅱ study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites[J]. Gynecol Oncol, 2012, 125(1): 42-47. DOI: 10.1016/j.ygyno.2011.11.021.
|
| [18] |
Tew WP, Colombo N, Ray-Coquard I, et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study[J]. Cancer, 2014, 120(3): 335-343. DOI: 10.1002/cncr.28406.
|
| [19] |
Rahma OE, Tyan K, Giobbie-Hurder A, et al. Phase ⅠB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors[J]. J Immunother Cancer, 2022, 10(3): e003569. DOI: 10.1136/jitc-2021-003569.
|
| [20] |
Coleman N, Stephen B, Fu S, et al. Phase Ⅰ study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors[J]. Cancer Med, 2024, 13(3): e6877. DOI: 10.1002/cam4.6877.
|
| [21] |
国家药品监督管理局. 国家药监局批准注射用苏维西塔单抗上市[EB/OL]. (2025-07-02) [2025-10-01].
URL
|
| [22] |
Yuan G, Lou G, Li J, et al. Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial[J]. Nat Cancer, 2026, 7(1): 182-193. DOI: 10.1038/s43018-025-01085-z.
|
| [23] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology for China: ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 3.2025) [EB/OL]. (2025-11-20) [2026-06-20].
URL
|
| [24] |
中华医学会妇科肿瘤学分会. 中国妇科肿瘤临床实践指南2025版[M]. 北京：中华医学电子音像出版社，2025.
|
| [25] |
|
| [26] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)卵巢癌诊疗指南2025[M]. 北京：人民卫生出版社，2025.
|
| [27] |
|
| [28] |
中国临床肿瘤学会妇科肿瘤专家委员会. 抗血管生成小分子酪氨酸激酶抑制剂在复发转移或晚期妇科肿瘤中的临床应用中国专家共识(2025)[J]. 中国实用妇科与产科杂志， 2025, 41(6): 639-648. DOI: 10.19538/j.fk2025060114. |
| [29] |
Zhu Y, Wang X, Chen Z, et al. Anlotinib suppressed ovarian cancer progression via inducing G2/M phase arrest and apoptosis[J]. J Clin Med， 2022， 12(1)：162. DOI： 10.3390/jcm12010162.
|
| [30] |
Ji Y, Li X, Qi Y, et al. Anlotinib exerts inhibitory effects against cisplatin-resistant ovarian cancer in vitro and in vivo[J]. Molecules, 2022, 27(24): 8873. DOI: 10.3390/molecules27248873.
|
| [31] |
Cui Q, Hu Y, Ma D, et al. A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer[J]. Drug Des Devel Ther, 2021, 15: 339-347. DOI: 10.2147/DDDT.S286529.
|
| [32] |
He Y, Zhai A, Qin K, et al. Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer[J]. Discov Oncol, 2024, 15(1): 383. DOI: 10.1007/s12672-024-01267-8.
|
| [33] |
Wu Y, Li P, Zhu Y, et al. Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study[J]. Am J Transl Res, 2023, 15(3): 1973-1981.
|
| [34] |
Shen W, Jing C, Tian W, et al. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase Ⅱ study[J]. Int J Gynecol Cancer, 2023, 33(11): 1764-1770. DOI: 10.1136/ijgc-2023-004777.
|
| [35] |
|
| [36] |
Liu G, Feng Y, Li J, et al. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: efficacy and safety results from the phase Ⅱ，multi-center ANNIE study[J]. EClin Med, 2022, 54: 101767. DOI: 10.1016/j.eclinm.2022.101767.
|
| [37] |
Huang S, Sheng G, Lv Q, et al. Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer[J]. J Gynecol Oncol, 2024, 35(6): e100. DOI: 10.3802/jgo.2024.35.e100.
|
| [38] |
Zhou K, Zhang JW, Wang QZ, et al. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice[J]. Acta Pharmacol Sin, 2019, 40(4): 556-562. DOI: 10.1038/s41401-018-0058-y.
|
| [39] |
Miao M, Deng G, Luo S, et al. A phase Ⅱ study of apatinib in patients with recurrent epithelial ovarian cancer[J]. Gynecol Oncol, 2018, 148(2): 286-290. DOI: 10.1016/j.ygyno.2017.12.013.
|
| [40] |
Wang T, Tang J, Yang H, et al. Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the approve randomized clinical trial[J]. JAMA Oncol, 2022, 8(8): 1169-1176. DOI: 10.1001/jamaoncol.2022.2253.
|
| [41] |
Wang W, Liu F, Qiu S, et al. Efficacy and safety of apatinib in the treatment of patients with platinum-resistant ovarian cancer: a systematic review and network Meta-analysis[J]. Exp Ther Med, 2024, 28(4): 376. DOI: 10.3892/etm.2024.12665.
|
| [42] |
Nicum S, McGregor N, Austin R, et al. Results of a randomised phase Ⅱ trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer[J]. Br J Cancer, 2024, 130(6): 941-950. DOI: 10.1038/s41416-023-02567-6.
|
| [43] |
Lee JM, Brady MF, Miller A, et al. Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005[J]. J Clin Oncol, 2024, 42(36): 4305-4316. DOI: 10.1200/JCO.24.00683.
|
| [44] |
Chekerov R, Hilpert F, Mahner S, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2018, 19(9): 1247-1258. DOI: 10.1016/S1470-2045(18)30372-3.
|
| [45] |
Pignata S, Lorusso D, Scambia G, et al. MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2015, 16(5): 561-568. DOI: 10.1016/S1470-2045(15)70115-4.
|
| [46] |
Duska LR, Petroni GR, Varhegyi N, et al. A randomized phase Ⅱ evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma[J]. Gynecol Oncol, 2020, 157(3): 585-592. DOI: 10.1016/j.ygyno.2019.10.014.
|
| [47] |
du Bois A, Kristensen G, Ray-Coquard I, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet Oncol, 2016, 17(1): 78-89. DOI: 10.1016/S1470-2045(15)00366-6.
|
| [48] |
Secord AA, McCollum M, Davidson BA, et al. Phase Ⅱ trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer[J]. Gynecol Oncol, 2019， 153(3): 555-561. DOI: 10.1016/j.ygyno.2019.03.246.
|
| [49] |
Peeters M, Strickland A, Lichinitser M, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma[J]. Br J Cancer, 2013, 108(3): 503-511. DOI: 10.1038/bjc.2012.594.
|
| [50] |
Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial[J]. Lancet Oncol, 2014, 15(8): 799-808. DOI: 10.1016/S1470-2045(14)70244-X.
|
| [51] |
Marth C, Vergote I, Scambia G, et al. ENGOT-ov-6/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer[J]. Eur J Cancer, 2017, 70: 111-121. DOI: 10.1016/j.ejca.2016.09.004.
|
| [52] |
Vergote I, Scambia G, O′Malley DM, et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2019, 20(6): 862-876. DOI: 10.1016/S1470-2045(19)30178-0.
|
| [53] |
|